APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenza A Virus, H3N2 Subtype Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Influenza A Virus, H3N2 Subtype Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174002650319 December 2025196 pages

Choose your research edition.

Industry ResearchInfluenza A Virus, H3N2 Subtype Infections Drug Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza A Virus, H3N2 Subtype Infections Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Influenza A Virus, H3N2 Subtype Infections Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Influenza A Virus, H3N2 Subtype Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug include Johnson & Johnson, AbbVie Inc, Zydus Cadila Healthcare Limited, Visterra, Inc., VBI Vaccines Inc., Sarepta Therapeutics, Inc., OPKO Health, Inc., NanoViricides, Inc. and Mucosis B.V., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenza A Virus, H3N2 Subtype Infections Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza A Virus, H3N2 Subtype Infections Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza A Virus, H3N2 Subtype Infections Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza A Virus, H3N2 Subtype Infections Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Company

Johnson & Johnson

AbbVie Inc

Zydus Cadila Healthcare Limited

Visterra, Inc.

VBI Vaccines Inc.

Sarepta Therapeutics, Inc.

OPKO Health, Inc.

NanoViricides, Inc.

Mucosis B.V.

MedImmune, LLC

Medicago Inc.

Inovio Pharmaceuticals, Inc.

ILiAD Biotechnologies, LLC

Glide Pharmaceutical Technologies Limited

FluGen, Inc.

Celltrion, Inc.

Aphios Corporation

AIMM Therapeutics B.V.

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Type

NVINF-1

NSC-61610

NP-025

NEO-8877

Others

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Application

Clinic

Hospital

Others

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza A Virus, H3N2 Subtype Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza A Virus, H3N2 Subtype Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza A Virus, H3N2 Subtype Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza A Virus, H3N2 Subtype Infections Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenza A Virus, H3N2 Subtype Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Influenza A Virus, H3N2 Subtype Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Influenza A Virus, H3N2 Subtype Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends Table 2. Influenza A Virus, H3N2 Subtype Infections Drug Industry Drivers Table 3. Influenza A Virus, H3N2 Subtype Infections Drug Industry Opportunities and Challenges Table 4. Influenza A Virus, H3N2 Subtype Infections Drug Industry Restraints Table 5. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Manufacturers Table 9. Global Influenza A Virus, H3N2 Subtype Infections Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Influenza A Virus, H3N2 Subtype Infections Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Influenza A Virus, H3N2 Subtype Infections Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers, Product Type & Application Table 13. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza A Virus, H3N2 Subtype Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of NVINF-1 Table 17. Major Manufacturers of NSC-61610 Table 18. Major Manufacturers of NP-025 Table 19. Major Manufacturers of NEO-8877 Table 20. Major Manufacturers of Others Table 21. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2021-2026) Table 25. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2027-2032) Table 26. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2021-2026) Table 30. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2021-2026) Table 38. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2027-2032) Table 39. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2021-2026) Table 43. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2027-2032) Table 44. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2021-2026) Table 47. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2021-2026) Table 65. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2027-2032) Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. AbbVie Inc Company Information Table 72. AbbVie Inc Business Overview Table 73. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 75. AbbVie Inc Recent Development Table 76. Zydus Cadila Healthcare Limited Company Information Table 77. Zydus Cadila Healthcare Limited Business Overview Table 78. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 80. Zydus Cadila Healthcare Limited Recent Development Table 81. Visterra, Inc. Company Information Table 82. Visterra, Inc. Business Overview Table 83. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 85. Visterra, Inc. Recent Development Table 86. VBI Vaccines Inc. Company Information Table 87. VBI Vaccines Inc. Business Overview Table 88. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 90. VBI Vaccines Inc. Recent Development Table 91. Sarepta Therapeutics, Inc. Company Information Table 92. Sarepta Therapeutics, Inc. Business Overview Table 93. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 95. Sarepta Therapeutics, Inc. Recent Development Table 96. OPKO Health, Inc. Company Information Table 97. OPKO Health, Inc. Business Overview Table 98. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 100. OPKO Health, Inc. Recent Development Table 101. NanoViricides, Inc. Company Information Table 102. NanoViricides, Inc. Business Overview Table 103. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 105. NanoViricides, Inc. Recent Development Table 106. Mucosis B.V. Company Information Table 107. Mucosis B.V. Business Overview Table 108. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 110. Mucosis B.V. Recent Development Table 111. MedImmune, LLC Company Information Table 112. MedImmune, LLC Business Overview Table 113. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 115. MedImmune, LLC Recent Development Table 116. Medicago Inc. Company Information Table 117. Medicago Inc. Business Overview Table 118. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 120. Medicago Inc. Recent Development Table 121. Inovio Pharmaceuticals, Inc. Company Information Table 122. Inovio Pharmaceuticals, Inc. Business Overview Table 123. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 125. Inovio Pharmaceuticals, Inc. Recent Development Table 126. ILiAD Biotechnologies, LLC Company Information Table 127. ILiAD Biotechnologies, LLC Business Overview Table 128. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 130. ILiAD Biotechnologies, LLC Recent Development Table 131. Glide Pharmaceutical Technologies Limited Company Information Table 132. Glide Pharmaceutical Technologies Limited Business Overview Table 133. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 135. Glide Pharmaceutical Technologies Limited Recent Development Table 136. FluGen, Inc. Company Information Table 137. FluGen, Inc. Business Overview Table 138. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 140. FluGen, Inc. Recent Development Table 141. Celltrion, Inc. Company Information Table 142. Celltrion, Inc. Business Overview Table 143. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 145. Celltrion, Inc. Recent Development Table 146. Aphios Corporation Company Information Table 147. Aphios Corporation Business Overview Table 148. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 150. Aphios Corporation Recent Development Table 151. AIMM Therapeutics B.V. Company Information Table 152. AIMM Therapeutics B.V. Business Overview Table 153. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 155. AIMM Therapeutics B.V. Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Influenza A Virus, H3N2 Subtype Infections Drug Distributors List Table 159. Influenza A Virus, H3N2 Subtype Infections Drug Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Influenza A Virus, H3N2 Subtype Infections Drug Product Image Figure 2. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (2021-2032) & (K Units) Figure 5. Global Influenza A Virus, H3N2 Subtype Infections Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Influenza A Virus, H3N2 Subtype Infections Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. NVINF-1 Image Figure 9. NSC-61610 Image Figure 10. NP-025 Image Figure 11. NEO-8877 Image Figure 12. Others Image Figure 13. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2021-2032) Figure 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2021-2032) Figure 25. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2032) Figure 42. China Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Influenza A Virus, H3N2 Subtype Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Influenza A Virus, H3N2 Subtype Infections Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Influenza A Virus, H3N2 Subtype Infections Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • NVINF-1
  • NSC-61610
  • NP-025
  • NEO-8877
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Johnson & Johnson
  • AbbVie Inc
  • Zydus Cadila Healthcare Limited
  • Visterra, Inc.
  • VBI Vaccines Inc.
  • Sarepta Therapeutics, Inc.
  • OPKO Health, Inc.
  • NanoViricides, Inc.
  • Mucosis B.V.
  • MedImmune, LLC
  • Medicago Inc.
  • Inovio Pharmaceuticals, Inc.
  • ILiAD Biotechnologies, LLC
  • Glide Pharmaceutical Technologies Limited
  • FluGen, Inc.
  • Celltrion, Inc.
  • Aphios Corporation
  • AIMM Therapeutics B.V.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Dynamics
  1. 2.1 Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends
  2. 2.2 Influenza A Virus, H3N2 Subtype Infections Drug Industry Drivers
  3. 2.3 Influenza A Virus, H3N2 Subtype Infections Drug Industry Opportunities and Challenges
  4. 2.4 Influenza A Virus, H3N2 Subtype Infections Drug Industry Restraints
3 Influenza A Virus, H3N2 Subtype Infections Drug Market by Manufacturers
  1. 3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenza A Virus, H3N2 Subtype Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers, Product Type & Application
  7. 3.7 Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenza A Virus, H3N2 Subtype Infections Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenza A Virus, H3N2 Subtype Infections Drug Tier 1, Tier 2, and Tier 3
4 Influenza A Virus, H3N2 Subtype Infections Drug Market by Type
  1. 4.1 Influenza A Virus, H3N2 Subtype Infections Drug Type Introduction
  2. 4.1.1 NVINF-1
  3. 4.1.2 NSC-61610
  4. 4.1.3 NP-025
  5. 4.1.4 NEO-8877
  6. 4.1.5 Others
  7. 4.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type
  8. 4.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type
  12. 4.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2021-2032)
5 Influenza A Virus, H3N2 Subtype Infections Drug Market by Application
  1. 5.1 Influenza A Virus, H3N2 Subtype Infections Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application
  6. 5.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application
  10. 5.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2021-2032)
6 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region
  1. 6.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region
  1. 7.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region
  2. 7.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032)
  8. 7.2.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032)
  11. 7.3.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 AbbVie Inc
  8. 8.2.1 AbbVie Inc Company Information
  9. 8.2.2 AbbVie Inc Business Overview
  10. 8.2.3 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  12. 8.2.5 AbbVie Inc Recent Developments
  13. 8.3 Zydus Cadila Healthcare Limited
  14. 8.3.1 Zydus Cadila Healthcare Limited Company Information
  15. 8.3.2 Zydus Cadila Healthcare Limited Business Overview
  16. 8.3.3 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  18. 8.3.5 Zydus Cadila Healthcare Limited Recent Developments
  19. 8.4 Visterra, Inc.
  20. 8.4.1 Visterra, Inc. Company Information
  21. 8.4.2 Visterra, Inc. Business Overview
  22. 8.4.3 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  24. 8.4.5 Visterra, Inc. Recent Developments
  25. 8.5 VBI Vaccines Inc.
  26. 8.5.1 VBI Vaccines Inc. Company Information
  27. 8.5.2 VBI Vaccines Inc. Business Overview
  28. 8.5.3 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  30. 8.5.5 VBI Vaccines Inc. Recent Developments
  31. 8.6 Sarepta Therapeutics, Inc.
  32. 8.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 8.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 8.6.3 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  36. 8.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 8.7 OPKO Health, Inc.
  38. 8.7.1 OPKO Health, Inc. Company Information
  39. 8.7.2 OPKO Health, Inc. Business Overview
  40. 8.7.3 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  42. 8.7.5 OPKO Health, Inc. Recent Developments
  43. 8.8 NanoViricides, Inc.
  44. 8.8.1 NanoViricides, Inc. Company Information
  45. 8.8.2 NanoViricides, Inc. Business Overview
  46. 8.8.3 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  48. 8.8.5 NanoViricides, Inc. Recent Developments
  49. 8.9 Mucosis B.V.
  50. 8.9.1 Mucosis B.V. Company Information
  51. 8.9.2 Mucosis B.V. Business Overview
  52. 8.9.3 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  54. 8.9.5 Mucosis B.V. Recent Developments
  55. 8.10 MedImmune, LLC
  56. 8.10.1 MedImmune, LLC Company Information
  57. 8.10.2 MedImmune, LLC Business Overview
  58. 8.10.3 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  60. 8.10.5 MedImmune, LLC Recent Developments
  61. 8.11 Medicago Inc.
  62. 8.11.1 Medicago Inc. Company Information
  63. 8.11.2 Medicago Inc. Business Overview
  64. 8.11.3 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  66. 8.11.5 Medicago Inc. Recent Developments
  67. 8.12 Inovio Pharmaceuticals, Inc.
  68. 8.12.1 Inovio Pharmaceuticals, Inc. Company Information
  69. 8.12.2 Inovio Pharmaceuticals, Inc. Business Overview
  70. 8.12.3 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  72. 8.12.5 Inovio Pharmaceuticals, Inc. Recent Developments
  73. 8.13 ILiAD Biotechnologies, LLC
  74. 8.13.1 ILiAD Biotechnologies, LLC Company Information
  75. 8.13.2 ILiAD Biotechnologies, LLC Business Overview
  76. 8.13.3 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  78. 8.13.5 ILiAD Biotechnologies, LLC Recent Developments
  79. 8.14 Glide Pharmaceutical Technologies Limited
  80. 8.14.1 Glide Pharmaceutical Technologies Limited Company Information
  81. 8.14.2 Glide Pharmaceutical Technologies Limited Business Overview
  82. 8.14.3 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  84. 8.14.5 Glide Pharmaceutical Technologies Limited Recent Developments
  85. 8.15 FluGen, Inc.
  86. 8.15.1 FluGen, Inc. Company Information
  87. 8.15.2 FluGen, Inc. Business Overview
  88. 8.15.3 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  90. 8.15.5 FluGen, Inc. Recent Developments
  91. 8.16 Celltrion, Inc.
  92. 8.16.1 Celltrion, Inc. Company Information
  93. 8.16.2 Celltrion, Inc. Business Overview
  94. 8.16.3 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  96. 8.16.5 Celltrion, Inc. Recent Developments
  97. 8.17 Aphios Corporation
  98. 8.17.1 Aphios Corporation Company Information
  99. 8.17.2 Aphios Corporation Business Overview
  100. 8.17.3 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  102. 8.17.5 Aphios Corporation Recent Developments
  103. 8.18 AIMM Therapeutics B.V.
  104. 8.18.1 AIMM Therapeutics B.V. Company Information
  105. 8.18.2 AIMM Therapeutics B.V. Business Overview
  106. 8.18.3 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  108. 8.18.5 AIMM Therapeutics B.V. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza A Virus, H3N2 Subtype Infections Drug Value Chain Analysis
  2. 9.1.1 Influenza A Virus, H3N2 Subtype Infections Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza A Virus, H3N2 Subtype Infections Drug Production Mode & Process
  6. 9.2 Influenza A Virus, H3N2 Subtype Infections Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza A Virus, H3N2 Subtype Infections Drug Distributors
  9. 9.2.3 Influenza A Virus, H3N2 Subtype Infections Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst